All articles tagged with #placebo
A 3-week open-label placebo study with 90 healthy older adults found that participants who knew they were taking inert pills still saw improvements in memory, physical performance, stress, and well-being, with effects often strongest when individuals believed they were taking an active treatment; results highlight the mind’s power in aging and suggest open-label placebos as an ethical tool for healthy aging.
In a small randomized trial of 35 participants with recurring depression, a single dose of psilocybin plus psychological support reduced depressive symptoms within days and provided benefits for just over three months versus placebo, where over half the psilocybin group no longer met depression criteria by six weeks, compared with limited improvement in the placebo group. After a year, the gap narrowed as placebo participants improved, highlighting the influence of expectations and the challenges of blinding. The study suggests psilocybin could help broader forms of depression but requires cautious interpretation and further research.
A 20-day randomized, placebo-controlled study by researchers at the University of Lancashire found that taking 100 microliters of peppermint oil twice daily lowered systolic blood pressure by about 8.5 mmHg in adults with prehypertension or stage 1 hypertension, suggesting peppermint oil as a low-cost, well-tolerated option to help manage mild hypertension; the authors call for further research.
Experts say there’s limited clinical evidence that supplement stacks extend lifespan; any perceived benefits are likely due to placebo or unproven effects, so focus on evidence-based healthy-aging practices instead.
Carol Tavris reviews Helen Pilcher’s This Book May Cause Side Effects, examining how negative expectations can produce real symptoms and influence medical outcomes. She highlights compelling examples (like statin side effects mirroring placebo) but critiques the book for overgeneralizing the idea that all illness can be worsened by nocebo and for lacking precise data in places. Still, she notes useful implications and strategies—reframing supposed side effects, emphasizing the majority who don’t experience them, and pursuing personalized informed consent—to counter the nocebo effect in clinical care.
A trial with adults 75+ in Milan found that behaving as if they were younger (in a 1989-era setting) improved strength, balance, gait, and self-rated youth. While results are preliminary and under peer review, the findings support a mind–body link in aging and suggest that expectations and cultural narratives can influence physical aging.
A Nature Medicine study shows that positive expectations can enhance the immune response to vaccines, illustrating a neural mechanism behind the placebo effect and suggesting mind-over-matter strategies could improve vaccination efficacy.
A tester reviews multiple wellness patches marketed for energy, sleep, focus, and cramps, finding little solid evidence they work; effects are largely placebo and vary by person and patch, with costs and ingredients under-regulated in many cases. The piece concludes patches are a cosmetic, “handbag health” trend rather than a cure-all, not a substitute for sleep hygiene or medical care.
A randomized trial provides direct human evidence that the placebo effect can shape humoral immunity: reward-related brain activity correlates with vaccine-induced antibody production, suggesting new ways to influence immune responses beyond the vaccine itself.
This study explores the neural and molecular effects of a 7-day mind-body retreat combining meditation, reconceptualization, and healing rituals, revealing significant changes in brain connectivity, neuroplasticity markers, metabolic pathways, immune responses, and exosomal RNAs, suggesting systemic physiological and psychological benefits beyond placebo effects.
A large, rigorous clinical trial found that repeated ketamine infusions do not provide additional benefits over standard inpatient care for major depression, with no significant differences in depression scores, cognition, or quality of life compared to placebo, highlighting the need for cautious clinical use and reevaluation of ketamine's efficacy.
RFK Jr. advocates for all new vaccines to be tested against placebos, but many experts argue this isn't always scientifically or ethically appropriate, especially when effective vaccines already exist. The debate centers on balancing rigorous safety testing with ethical considerations, as most childhood vaccines were historically tested against placebos, but modern standards often prevent placebo use when effective treatments are available.
A brain imaging study shows that expectations influence pain differently depending on whether they are shaped by external cues or treatment information, with cues affecting pain-related brain activity more reliably than placebo explanations, highlighting the importance of how healthcare providers communicate with patients.
A meta-analysis of 90 randomized controlled trials involving nearly 10,000 adults found that placebos can significantly improve symptoms of various mental health disorders, including depression and anxiety. The study supports the ethical use of placebo controls in clinical trials and suggests that initial non-medication approaches may be viable for some patients. However, for disorders like OCD and schizophrenia, medication remains crucial. The findings highlight the importance of belief in treatment and the natural course of mental disorders.
A study found that imagining taking a placebo pill is more effective at reducing visually induced disgust than actually ingesting a placebo pill. This novel approach to open-label placebo administration suggests significant potential for emotion regulation in both clinical and non-clinical settings.